This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Wu, M.
Right arrow Articles by Tsuji, B. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, M.
Right arrow Articles by Tsuji, B. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2009, p. 3992-3995, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.01597-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Vancomycin and Daptomycin Pharmacodynamics Differ against a Site-Directed Staphylococcus epidermidis Mutant Displaying the Small-Colony-Variant Phenotype {triangledown}

Marina Wu,1 Christof von Eiff,3 Nahed Al Laham,3 and Brian T. Tsuji1,2,4*

Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences,1 the New York State Center of Excellence in Bioinformatics & Life Sciences,2 University at Buffalo, Buffalo, New York; Institute of Medical Microbiology, University of Münster, Münster, Germany,3 Roswell Park Cancer Institute Department of Medicine, Buffalo, New York4

Received 2 December 2008/ Returned for modification 24 March 2009/ Accepted 18 June 2009

Catheter-related bloodstream infections due to slow-growing Staphylococcus epidermidis small-colony variants (SCVs) are extremely difficult to treat. Daptomycin and vancomycin pharmacodynamics were evaluated against a site-directed hemB mutant of S. epidermidis displaying the SCV phenotype and compared to that of the parental strain. The maximal killing effect decreased by 7.7-fold for vancomycin and 1.5-fold for daptomycin against the SCV mutant and were well characterized by a Hill-type mathematical model (R2 > 0.97).

* Corresponding author. Mailing address: Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, 316 Cooke Hall, University at Buffalo, Buffalo, NY 14260. Phone: (716) 881-7543. Fax: (716) 849-6890. E-mail: btsuji{at}buffalo.edu

{triangledown} Published ahead of print on 29 June 2009.

Antimicrobial Agents and Chemotherapy, September 2009, p. 3992-3995, Vol. 53, No. 9
0066-4804/09/$08.00+0     doi:10.1128/AAC.01597-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»